(37), MerTK inhibition by small molecule tyrosine kinase, MRX2843, could change the leukemia microenvironment from tumor-permissive toward immune responsiveness to leukemia, as well as enhance the AML clearance mediated by immune. Here, MERTK is linked to acute myeloid leukemia.